Case report: Vogt-Koyanagi-Harada-like uveitis induced by anti-PD-1 therapy (Sintilimab) in a gastric cancer patient: a case study.

Sintilimab is a PD-1 inhibitor used in China, and this report describes a case of Vogt-Koyanagi-Harada-like uveitis following its long-term use for gastric cancer.

CASE PRESENTATION: A 55-year-old man presented with a 1-week history of bilateral blurred vision and tinnitus.

His best-corrected visual acuity (BCVA) was 0.3 (approximately 6/20) in the right eye and 0.15 (approximately 6/40) in the left.

This case suggests that long-term therapy with sintilimab, a PD-1 antibody, can trigger Vogt-Koyanagi-Harada-like uveitis.